UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported): | | November 8, 2007 |
Auriga Laboratories, Inc.
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation) | | 000-26013 (Commission File Number) | | 84-1334687 (I.R.S. Employer Identification No.) |
| | | | | |
| | | | | |
10635 Santa Monica Boulevard, Suite 120 Los Angeles, California 90025 (Address of principal executive offices) (zip code) |
| | | | | |
| | | | | |
(310) 461-3600 (Registrant’s telephone number, including area code) |
| | | | | |
| | | | | |
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 2 - Financial Information
Item 2.02 Results of Operations and Financial Condition.
On November 8, 2007, we held a conference call to discuss our business highlights and third quarter earnings for the quarter ended September 30, 2007. A transcript of this conference call is furnished as an exhibit to this report as Exhibit 99.1 and is incorporated herein by reference. The recorded version of this conference call will be available on our website at www.aurigalabs.com for the next 30 days.
The information in this Current Report on Form 8-K, including Exhibits 99.1 attached hereto, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under such section, nor shall it be deemed incorporated by reference in any of our filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. We have posted a copy of this Current Report on Form 8-K on our website at www.aurigalabs.com.
Section 7 - Regulation FD
Item 7.01 Regulation FD Disclosure.
The information included under Item 2.02 above is incorporated herein by reference.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits
Exhibit No. | | Description |
| | | |
| 99.1 | | Transcript of Auriga Laboratories, Inc. conference call held November 8, 2007 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: November 8, 2007 | Auriga Laboratories, Inc. |
| | a Delaware corporation |
| | | |
| | | |
| | /s/ Philip S. Pesin | |
| | By: Philip S. Pesin |
| | Its: Chief Executive Officer |
